Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.46 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.46 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28311804 | 0.88 | ADRA2C (0.53) | HRH4ADRA2CGAAMAPTNCF1 | |
| SCHEMBL5451029 | 0.88 | MEN1 (0.52) | HSP90AA1HSP90AB1IDO1PSMB5HRH4 | |
| SCHEMBL15161267 | 0.84 | SMN1; SMN2 (0.56) | HRH4SMN1; SMN2GAAMEN1USP2 | |
| SCHEMBL27732003 | 0.82 | MAPT (0.62) | HSP90AA1HSP90AB1IDO1PSMB5SMN1; SMN2 | |
| SCHEMBL30744915 | 0.78 | KDM4E (0.57) | SMN1; SMN2GAAMEN1USP2LMNA | |
| SCHEMBL3623865 | 0.78 | ADRA2C (0.62) | HRH4ADRA2CGAAKMT2AMAPT | |
| SCHEMBL29509033 | 0.78 | ADRA2C (0.62) | HRH4ADRA2CGAAKMT2AMAPT | |
| SCHEMBL3627022 | 0.77 | MAPT (0.79) | HSP90AA1ADRA2CSMN1; SMN2MEN1USP2 | |
| SCHEMBL22858556 | 0.75 | METAP2 (0.46) | HSP90AA1HSP90AB1IDO1PSMB5HRH4 | |
| SCHEMBL18284881 | 0.74 | ADRA2C (0.58) | HRH4ADRA2CGAAMAPTNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2021003417-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | TNK1, TNNI3K, TYK2 | HSP90AA1 3028/4885HSP90AB1 2784/4885IDO1 1763/4885 |
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | HSP90AA1 1430/4885HSP90AB1 1494/4885IDO1 3029/4885 |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | TNK1, TNNI3K, TYK2 | HSP90AA1 3028/4885HSP90AB1 2784/4885IDO1 1763/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | HSP90AA1 1042/4885HSP90AB1 1204/4885IDO1 2723/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | HSP90AA1 1302/4885HSP90AB1 1256/4885IDO1 1126/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | HSP90AA1 1042/4885HSP90AB1 1204/4885IDO1 2723/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | HSP90AA1 1430/4885HSP90AB1 1494/4885IDO1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.